Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Amazon Restructures Healthcare Business to Drive Growth and Simplify Operations

by Team Lumida
June 17, 2025
in Markets
Reading Time: 4 mins read
A A
0
Amazon’s $100 Billion Bet: AI Over Retail

Source: RMC

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • Amazon Health Services (AHS) has been reorganized into six new divisions, each led by longtime Amazon executives or leaders from its$3.9 billion One Medical acquisition.
  • The restructuring aims to simplify AHS’ structure, accelerate innovation, and expand its healthcare offerings, including telehealth, chronic care management, and pharmacy services.
  • Despite past setbacks, such as the closure of Amazon Care and Haven, Amazon has seen momentum in healthcare, with strong uptake in pharmacy services and plans to expand One Medical offices.
  • The restructuring follows the departure of several high-level executives, including One Medical CEO Trent Green and Amazon Pharmacy’s Chief Medical Officer Dr. Vin Gupta.

What Happened?

Amazon has restructured its healthcare business, Amazon Health Services (AHS), into six new divisions to streamline operations and drive growth. The reorganization, completed in May, comes after mixed results in the healthcare sector and the departure of key executives.

The six divisions are led by a mix of longtime Amazon executives and leaders from One Medical, which Amazon acquired in 2023 for$3.9 billion. The restructuring reflects Amazon’s broader strategy to deliver better patient care and accelerate innovation across its healthcare offerings.

Amazon’s healthcare initiatives include telehealth, chronic condition management, pharmacy services, and a national physician network through One Medical. While some ventures, like Amazon Care and Haven, failed to gain traction, the company has recently reported strong momentum in pharmacy services and is expanding One Medical offices in states like New York, New Jersey, and Ohio.


Why It Matters?

Amazon’s restructuring highlights its commitment to becoming a major player in the healthcare industry, despite past challenges. The company’s focus on consumer-centric services, such as same-day medication delivery and caregiver-controlled drug orders, positions it to compete with traditional healthcare providers and other tech-driven entrants.

The reorganization also underscores the importance of leadership in driving innovation and growth. By appointing experienced Amazon executives and One Medical leaders to helm its new divisions, Amazon aims to leverage its expertise in logistics, technology, and customer experience to disrupt the healthcare sector.

However, the departure of high-level executives raises questions about the company’s ability to retain top talent and navigate the complexities of the healthcare industry.


What’s Next?

Amazon plans to continue expanding its healthcare footprint, with a focus on growing One Medical’s presence and enhancing its pharmacy offerings. The company’s ability to execute its restructured strategy will be critical to its success in the highly competitive and regulated healthcare market.

Investors and industry stakeholders will closely monitor Amazon’s progress, particularly in areas like telehealth, chronic care management, and partnerships with health systems. The company’s ability to innovate and scale its healthcare services will determine whether it can overcome past setbacks and establish itself as a leader in the sector.

Source
Previous Post

At Home Files for Chapter 11 Bankruptcy Amid Tariff Pressures and Mounting Debt

Next Post

Airbus to Boost Shareholder Returns Amid Strong Aircraft Demand

Recommended For You

Apple Guides a Big Holiday Quarter on iPhone 17 Upgrades; Services Top $100B

by Team Lumida
4 hours ago
Apple Guides a Big Holiday Quarter on iPhone 17 Upgrades; Services Top $100B

Key Takeaways Powered by lumidawealth.com September-quarter revenue $102.5B (+8% YoY) and shares +~3% after-hours. December-quarter guide: total revenue +10% to +12% YoY, led by double-digit iPhone growth. iPhone revenue...

Read more

Big Tech’s AI Capex Hits $78B in a Quarter, Testing Market Patience

by Team Lumida
1 day ago
a black square with a blue logo on it

Key Takeaways Powered by lumidawealth.com Alphabet, Meta, and Microsoft spent ~$78B on capex last quarter, +89% YoY, mostly for AI data centers and GPUs. Stocks split: Meta and Microsoft...

Read more

Tesla’s Cybercab Backup Plan: Sell It With a Steering Wheel

by Team Lumida
2 days ago
a car's speedometer with red lights

Key Takeaways Tesla board chair Robyn Denholm said Cybercab (long-promised affordable EV) can have steering wheel/pedals if needed—crucial wiggle room vs. Musk's "pointless" $25K regular model comment a...

Read more

Amazon to Lay Off Up to 30,000 Corporate Workers

by Team Lumida
3 days ago
Amazon’s $100 Billion Bet: AI Over Retail

Key Takeaways Powered by lumidawealth.com Amazon cutting up to 30,000 corporate employees (~10% of white-collar workforce) starting Tuesday, largest layoffs since 27,000 eliminated in 2022; hits HR, AWS, advertising,...

Read more

Gold Trading Talent War Heats Up as Bullion Boom Drives Hiring and Pay Surges

by Team Lumida
4 days ago
gold and black metal tool

Key Takeaways Powered by lumidawealth.com Major trading houses (Trafigura, Gunvor, IXM, Mercuria) and hedge funds are aggressively hiring gold traders amid soaring market activity. Banks historically dominated gold trading...

Read more

Microsoft Faces Legal Action in Australia Over Copilot Pricing Practices

by Team Lumida
4 days ago
The AI Investment Dilemma: Future-Proof or Financial Folly?

Key Takeaways Australia’s ACCC has sued Microsoft for allegedly misleading 2.7M Microsoft 365 subscribers on Copilot-related price hikes. Regulator claims Microsoft hid cheaper “classic” non-Copilot plans until users...

Read more

Wall Street Prices Optionality on Trump Tariffs Ahead of Supreme Court Ruling

by Team Lumida
6 days ago
Wall Street Prices Optionality on Trump Tariffs Ahead of Supreme Court Ruling

Key Takeaways Powered by lumidawealth.com Banks are brokering claims trades where importers sell future tariff-refund rights at a discount; hedge funds take legal risk for potential multi-bagger payouts. Typical...

Read more

Meta Charged by EU Over Handling of Illegal Content

by Team Lumida
7 days ago
a black square with a blue logo on it

Key Takeaways Powered by lumidawealth.com EU Commission charged Meta under Digital Services Act (DSA) for failing to provide simple illegal-content flagging and adequate appeal tools for content-moderation decisions on...

Read more

Trump Administration in Talks to Take Equity Stakes in Quantum-Computing Firms

by Team Lumida
1 week ago
Trump Administration in Talks to Take Equity Stakes in Quantum-Computing Firms

Key Takeaways Powered by lumidawealth.com Commerce Dept. negotiating equity stakes in quantum firms (IonQ, Rigetti, D-Wave, QCI, Atom Computing) in exchange for federal funding; minimum awards ~$10M each from...

Read more

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue

by Team Lumida
1 week ago
Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue

Key Takeaways Powered by lumidawealth.com Guidance raised: core EPS now high single-digit to low double-digit growth at CER (from high single-digit); full-year sales still mid-single-digit growth ex-FX. Q3 miss...

Read more
Next Post
white and blue airplane on airport during daytime

Airbus to Boost Shareholder Returns Amid Strong Aircraft Demand

Why Berkshire’s Latest Yen Bond Sale Could Ignite the Japanese Market

Japan’s Exports Decline for First Time in Eight Months Amid U.S. Tariff Pressures

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Tesla Supplier STMicroelectronics Expects Lower Annual Sales Amid Slow Recovery in Chip Demand

Tesla Supplier STMicroelectronics Expects Lower Annual Sales Amid Slow Recovery in Chip Demand

October 23, 2025
Trump Fires BLS Chief After Weak Jobs Report, Eyes More Fed Influence

Oil Jumps as Trump Steps Up Pressure on Russia With Sanctions

October 23, 2025
Biden’s Economic Legacy: A Boon or Burden for His Successor?

Biden Administration Set to Expand Global AI Chip Export Controls in Final Days

January 9, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018